Androgen Deprivation Therapy Market Strategies and Forecast by 2031

Historic Data: 2021-2023   |   Base Year: 2024   |   Forecast Period: 2025-2031

Coverage: Androgen Deprivation Therapy Market covers analysis By Drug Class (Antiandrogens, Luteinizing Hormone Releasing Hormone (LHRH) Agonists, LHRH Antagonists, and Other Drug Classes); Mode of Administration (Injectable and Oral); Distribution Channel (Hospital Pharmacies, Online Pharmacies and Retail Pharmacies), and Geography (North America, Europe, Asia Pacific, and South and Central America)

  • Report Code : TIPRE00008561
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

MARKET INTRODUCTION



Androgen deprivation therapy (ADT), also known as androgen suppression therapy, is carried out in men having prostate cancer. The pancreas is an androgen-dependent organ, and by providing ADT, it is possible to provide treatment for advanced and metastatic disease. Also, ADT is used along with external beam radiotherapy (EBRT) for intermediate to high-risk prostate cancer cases to improve responses to radiation. It is estimated that around 40% of patients diagnosed with prostate cancer would receive ADT within six months of diagnosis.

MARKET DYNAMICS



The androgen deprivation therapy market is anticipated to grow in the forecast, owing to the rise in the number of deaths caused due to prostate cancer, coupled with the rising demand for better medication. Also, the increase in R&D activities for the introduction of novel treatments for cancer is expected to offer significant growth opportunities in the market during the forecast period.

MARKET SCOPE



The "Androgen Deprivation Therapy Market Analysis to 2031" is a specialized and in-depth study of the pharmaceutical industry with a particular focus on the global market trend analysis. The report aims to provide an overview of the androgen deprivation therapy market with detailed market segmentation by drug class, mode of administration, distribution channel, and geography. The androgen deprivation therapy market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading androgen deprivation therapy market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION



The androgen deprivation therapy market is segmented based on drug class, mode of administration, and distribution channel. Based on drug class, the market is segmented as antiandrogens, luteinizing hormone-releasing hormone (LHRH) agonists, LHRH antagonists, and other drug classes. Based on the mode of administration, the market is categorized as injectable and oral. Based on the distribution channel, the market is segmented as hospital pharmacies, online pharmacies, and retail pharmacies.

REGIONAL FRAMEWORK



The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the androgen deprivation therapy market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The androgen deprivation therapy market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting androgen deprivation therapy market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the androgen deprivation therapy market in these regions.


MARKET PLAYERS



The report covers key developments in the androgen deprivation therapy market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from androgen deprivation therapy market are anticipated to have lucrative growth opportunities in the future with the rising demand for androgen deprivation therapy market in the global market. Below mentioned is the list of few companies engaged in the androgen deprivation therapy market.

The report also includes the profiles of key androgen deprivation therapy market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

- Allergan, Inc.
- Amgen Inc.
- Astellas Pharma Inc.
- AstraZeneca
- Bayer AG
- Johnson & Johnson Services, Inc.
- Orion Corporation
- Pfizer Inc.
- Sanofi
- Veru Inc.

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.

Androgen Deprivation Therapy Report Scope

Report Attribute Details
Market size in 2024 US$ XX million
Market Size by 2031 US$ XX Million
Global CAGR (2025 - 2031) XX%
Historical Data 2021-2023
Forecast period 2025-2031
Segments Covered By Drug Class
  • Antiandrogens
  • Luteinizing Hormone Releasing Hormone Agonists
  • LHRH Antagonists
  • Other Drug Classes
By Mode of Administration
  • Injectable and Oral
By Distribution Channel
  • Hospital Pharmacies
  • Online Pharmacies and Retail Pharmacies
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Allergan, Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca
  • Bayer AG
  • Johnson & Johnson Services, Inc.
  • Orion Corporation
  • Pfizer Inc.
  • Sanofi
    • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
    • PEST and SWOT Analysis
    • Market Size Value / Volume - Global, Regional, Country
    • Industry and Competitive Landscape
    • Excel Dataset
    androgen-deprivation-therapy-market-report-deliverables-img1
    androgen-deprivation-therapy-market-report-deliverables-img2
    Report Coverage

    Report Coverage

    Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

    Segment Covered

    Segment Covered

    This text is related
    to segments covered.

    Regional Scope

    Regional Scope

    North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

    Country Scope

    Country Scope

    This text is related
    to country scope.

    Trends and growth analysis reports related to Life Sciences : READ MORE..   

    Androgen Deprivation Therapy Market
    Connect With Expert
    The List of Companies

    1. Allergan, Inc.
    2. Amgen Inc.
    3. Astellas Pharma Inc.
    4. AstraZeneca
    5. Bayer AG
    6. Johnson & Johnson Services, Inc.
    7. Orion Corporation
    8. Pfizer Inc.
    9. Sanofi
    10. Veru Inc.
    androgen-deprivation-therapy-market-cagr